(Q40356056)

19 September 2017

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment (English)

1 reference

19 September 2017

1 reference

1 reference

1 reference

1

Fred Poordad

0 references

Mark Sulkowski

4

object named as

Mark S Sulkowski

1 reference

19 September 2017

Franco Felizarta

2

1 reference

19 September 2017

Armen Asatryan

3

1 reference

19 September 2017

Robert W Reindollar

5

1 reference

19 September 2017

Charles S Landis

6

1 reference

19 September 2017

Stuart C Gordon

7

1 reference

19 September 2017

Steven L Flamm

8

1 reference

19 September 2017

Michael W Fried

9

1 reference

19 September 2017

David E Bernstein

10

1 reference

19 September 2017

Chih-Wei Lin

11

1 reference

19 September 2017

Ran Liu

12

1 reference

19 September 2017

Sandra S Lovell

13

1 reference

19 September 2017

Teresa I Ng

14

1 reference

19 September 2017

Jens Kort

15

1 reference

19 September 2017

Federico J Mensa

16

1 reference

19 September 2017

language of work or name

English

0 references

publication date

27 January 2017

1 reference

19 September 2017

1 reference

19 September 2017

66

1 reference

19 September 2017

2

1 reference

19 September 2017

389-397

1 reference

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir

19 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Successes and Challenges on the Road to Cure Hepatitis C

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Global epidemiology and genotype distribution of the hepatitis C virus infection

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Global distribution and prevalence of hepatitis C virus genotypes

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Update on hepatitis C virus resistance to direct-acting antiviral agents

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

New hepatitis C therapies: the toolbox, strategies, and challenges

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5573922

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting: The Annual Meeting of the European Association for the Study of the Liver • April 13-17, 2016 • Barcelona, SpainSpecial Reporting

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28128852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment options of patients with chronic hepatitis C who have failed prior therapy

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FHEP.29081

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.29081

1 reference

19 September 2017

1 reference

19 September 2017

PubMed publication ID

28128852

1 reference